Clinical trials
Liver Cancer clinical trials
Below are recruiting liver cancer clinical trials, each written for real people, not researchers. We’re tracking 363 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06590259RecruitingPhase 2
Ablation plus drug therapy for colorectal cancer liver metastases
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
ShanghaiAges 18–75 - NCT07623265Recruiting
Understanding Immunotherapy Response in Liver Cancer
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
AntwerpAges 18 years+ - NCT06718530Recruiting
Finding early markers for liver cancer in people with chronic liver disease
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
Aviano, PordenoneAges 18 years+ - NCT06338215Recruiting
Moderate drinking vs. abstention advice for adults
This study compares two approaches for adults who drink regularly: advice on drinking in moderation vs. advice to stop drinking entirely. The goal is to see which approach better prevents major diseases and early death over time.
Pamplona, NavarreAges 50–75 - NCT07544784RecruitingPhase 2
AK104 plus radiation for colorectal cancer spread to liver
This study tests a new immunotherapy drug called AK104 combined with radiation therapy and standard chemotherapy for colorectal cancer that has spread to the liver. The goal is to see if adding AK104 and targeted radiation improves treatment outcomes compared to standard therapy alone.
ShanghaiAges 18 years+ - NCT07500220RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for advanced liver cancer
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07495215RecruitingPhase 1/Phase 2
Personalized mRNA vaccine plus immunotherapy for liver cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
Hangzhou, ZhejiangAges 18–75 - NCT06777628Recruiting
Blood test study to predict immunotherapy success in liver cancer
This study looks at blood cells from people with liver cancer (HCC) to see if we can predict early whether immunotherapy will work for them. It's a research study that involves blood tests during your normal care.
Bologna, Laura GramantieriAges 18 years+ - NCT07432347Recruiting
Decoding liver cancer immune evasion with advanced testing
This trial studies liver cancer tissue to understand how the tumor hides from the immune system. The goal is to use this knowledge to improve future treatments.
Milan, LombardyAges 18 years+ - NCT05010681RecruitingPhase 2
Lenvatinib plus immunotherapy after prior liver cancer treatment
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07345247Recruiting
Radiation segmentectomy for liver tumors using resin microspheres
This trial tests a precise radiation treatment for liver tumors. It uses tiny radioactive beads called resin microspheres to target cancer in a specific liver segment, which may help patients with hepatocellular carcinoma (a type of liver cancer) or tumors that have spread to the liver from elsewhere.
AdanaAges 18 years+ - NCT07295340Recruiting
New imaging dye test for liver cancer detection
This trial tests a special dye that targets liver cancer cells to help surgeons see tumor edges more clearly during surgery. It may help ensure all cancer is removed in one operation.
Chengdu, SichuanAges 18–80 - NCT07295262RecruitingEarly Phase 1
New imaging to guide liver cancer surgery
This trial tests a new imaging technique that uses a special dye combined with a chemotherapy drug to help surgeons see and remove liver cancer more precisely during surgery. It is for people with a first-time, single liver tumor that is small and can be surgically removed.
Chengdu, SichuanAges 18–75 - NCT07285850RecruitingPhase 2/Phase 3
Sequential treatment for advanced liver cancer with fatty liver
This trial tests a combination of two medications, bevacizumab and atezolizumab, given one after the other to treat advanced liver cancer that cannot be surgically removed. It is specifically for people whose liver cancer is linked to a fatty liver condition (MASLD). The goal is to see if this approach helps shrink tumors or control the disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06641713Recruiting
Comparing two liver cancer treatments for large tumors
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
Beijing, Beijing MunicipalityAges 18–75 - NCT06899854Recruiting
Collecting blood and tissue from patients with liver cancer
This study collects blood and tumor tissue samples from people with primary liver cancer who are starting their first treatment (systemic therapy or surgery). The samples help researchers learn more about these cancers and how to improve future treatments.
Pavia, PaviaAges 18–90 - NCT06898398Recruiting
TACE before surgery for large liver cancer
This trial combines a procedure called TACE (which blocks the blood supply to the tumor) with surgery to remove a large liver tumor. It is for people newly diagnosed with a large liver cancer that hasn't spread and can be completely removed with surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT06844357RecruitingPhase 2/Phase 3
New embolization vs standard for liver cancer
This trial tests a new embolization treatment (TATE) against standard therapy for people with intermediate-stage liver cancer that hasn't spread. The goal is to see if TATE works better at controlling the tumor.
Nanjing, JiangsuAges 18 years+ - NCT07186010Recruiting
Immune therapy biomarkers in advanced liver cancer
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
Seoul, Song-paAges 19 years+ - NCT07174570RecruitingPhase 2
Celecoxib with immunotherapy for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a pain reliever (celecoxib) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug combination works better than standard treatments.
Atlanta, GeorgiaAges 18 years+ - NCT07169656Recruiting
Study on reducing liver cancer risk in hepatitis B patients
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
AnyangAges 18 years+ - NCT07166406RecruitingPhase 3
Immunotherapy with or without targeted radiation for advanced liver cancer
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
Berkeley, CaliforniaAges 18 years+ - NCT06950814Recruiting
Impact of extra treatment after surgery for liver cancer
This study looks at whether additional treatment after liver surgery (like chemotherapy or radiation) can help people with a rare and aggressive liver cancer called primary hepatic sarcomatoid carcinoma (PHSC). It only includes people who had surgery and no other cancer treatments before that.
Chengdu, SichuanAges 18 years+ - NCT06914648Recruiting
Liver preparation before surgery study for certain liver cancers
This study tests a procedure called portal vein embolization (PVE) to help grow the healthy part of the liver before surgery. It may be an option for people with certain liver cancers who need more healthy liver tissue before their operation.
New Haven, ConnecticutAges 18 years+
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer?
- Yes. Clin2 currently lists 363 recruiting liver cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.